Generic Haldol ( Haloperidol )

Order cheap Generic Haldol (Haloperidol) without dr prescription in the United States

In our USA pharmacy, you can buy Haldol without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Haldol (haloperidol) is a high‑potency first‑generation antipsychotic (butyrophenone) that works by blocking dopamine D2 receptors in the brain, thereby reducing psychotic symptoms such as hallucinations, delusions, and disorganized thinking. It is also effective for severe motor and vocal tics in Tourette syndrome and for managing acute agitation.
Usual adult dose: For moderate to severe psychotic disorders, 5‑10 mg two to three times daily, adjusted gradually based on response and tolerability; the 10 mg tablet is often used in maintenance therapy for patients stabilized on this dose. Maximum daily oral dose is 100 mg. For Tourette syndrome, doses are typically lower and individually titrated.
Dosage form: Oral tablet (10 mg; also available as 0.5 mg, 1 mg, 2 mg, 5 mg, and 20 mg tablets).
Onset of action: Initial calming effects may be seen within 2‑4 hours; full antipsychotic benefit often takes 2‑4 weeks of continuous therapy.
Duration of action: A single oral dose has a therapeutic effect of 12‑24 hours; the elimination half‑life ranges from 14 to 37 hours, supporting once‑daily or divided dosing.
Alcohol consumption must be strictly avoided. Alcohol potentiates central nervous system depression, increases the risk of extrapyramidal side effects, and can dangerously lower blood pressure.
Most common side effects: extrapyramidal symptoms (stiffness, tremor, restlessness), sedation, dry mouth, constipation, blurred vision, and orthostatic hypotension.
Would you like to try Haldol without a prescription?

General Information about Haldol

• INN (International Nonproprietary Name): Haloperidol
• Brand names available in the USA: Haldol® (Janssen Pharmaceuticals, Inc.) is the brand‑name product. Generic haloperidol tablets are manufactured by numerous FDA‑approved companies, including Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., and others.
• ATC code: N05AD01
• Dosage forms and strengths: Oral tablets: 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg. (Also available as an oral concentrate, injectable solution, and long‑acting decanoate injection.)
• Manufacturers in USA: Janssen Pharmaceuticals, Inc. (brand Haldol®); generic manufacturers include Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Sandoz Inc., and many other authorized generic distributors.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) (NDA 015920).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Haloperidol is a potent, centrally acting dopamine D2 receptor antagonist. By blocking postsynaptic D2 receptors in the mesolimbic pathway, it reduces the positive symptoms of psychosis (hallucinations, delusions). Its antagonism of D2 receptors in the nigrostriatal pathway is responsible for extrapyramidal side effects, while blockade in the tuberoinfundibular pathway increases prolactin secretion. Haloperidol also has moderate affinity for alpha‑1 adrenergic receptors (leading to orthostatic hypotension) and minimal affinity for histamine H1 and muscarinic receptors compared with low‑potency antipsychotics, resulting in less sedation and anticholinergic effects. After oral administration, absorption is rapid, with peak plasma concentrations occurring 2‑6 hours after a dose. The drug undergoes extensive first‑pass hepatic metabolism, primarily via CYP3A4 and to a lesser extent CYP2D6, with glucuronidation and reduction also contributing. The elimination half‑life is variable, ranging from 14 to 37 hours (average ~20 hours), and the active metabolite reduced haloperidol may contribute to the therapeutic effect. Steady‑state is achieved in about 3‑5 days. The drug is highly protein‑bound (~92%). Excretion occurs via urine and feces.

Indications

• Management of manifestations of psychotic disorders (e.g., schizophrenia).
• Control of tics and vocal utterances of Tourette syndrome in children and adults after failure of other treatments.
• Treatment of severe behavioral problems in children with combative, explosive hyperexcitability that cannot be accounted for by immediate provocation (second‑line, short‑term).
• Acute management of agitation, aggression, and delirium (often given intramuscularly or intravenously in emergency settings).
• Off‑label uses include treatment of intractable hiccups, Huntington chorea, and severe nausea/vomiting unresponsive to other measures.

Important Warnings and Precautions

Haldol carries a boxed warning for increased mortality in elderly patients with dementia‑related psychosis. Antipsychotics are not approved for the treatment of dementia‑related behavioral disturbances; cerebrovascular adverse events, including stroke and transient ischemic attack, have been reported. Haloperidol is associated with a dose‑related risk of QT prolongation and torsades de pointes, particularly when given intravenously or in high doses; ECG monitoring is recommended. Neuroleptic malignant syndrome (NMS), a potentially fatal syndrome of hyperthermia, muscle rigidity, autonomic instability, and altered consciousness, can occur; discontinue Haldol immediately if NMS is suspected. Tardive dyskinesia, a potentially irreversible syndrome of involuntary movements, may develop with prolonged use; the lowest effective dose for the shortest duration is advised. Extrapyramidal symptoms (dystonia, akathisia, parkinsonism) are common and may require dose reduction or anticholinergic medication. Haloperidol lowers the seizure threshold; use with caution in patients with a history of seizures. Severe hepatotoxicity (cholestatic jaundice) has been reported. Hyperprolactinemia can cause galactorrhea, gynecomastia, and menstrual disturbances. Orthostatic hypotension may occur, particularly with parenteral administration.

At‑risk groups

• Elderly: Increased sensitivity to extrapyramidal symptoms, anticholinergic effects, and orthostatic hypotension. Initiate with low doses (0.5‑2 mg twice daily) and titrate cautiously. Not recommended for dementia‑related psychosis.
• Pregnancy: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates exposed to antipsychotics in the third trimester are at risk for extrapyramidal symptoms and withdrawal. Haloperidol crosses the placenta.
• Breastfeeding: Haloperidol is excreted into human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
• Renal impairment: No specific dose adjustment is required; however, metabolites are renally cleared, and accumulation may occur with severe impairment. Use with caution.
• Hepatic impairment: Contraindicated in patients with severe hepatic impairment or active liver disease. Use with caution in mild to moderate impairment; lower doses may be required due to reduced metabolism.
• Pediatric: Safety and efficacy have been established for Tourette syndrome and severe behavioral disorders; dosing is weight‑based and must be carefully titrated. For Tourette syndrome, starting dose is 0.05 mg/kg/day, gradually increased. The 10 mg tablet is generally not used in young children.
• Cardiovascular disease: Contraindicated in patients with pre‑existing QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or history of ventricular arrhythmias. Use with caution in other cardiac conditions; ECG monitoring is essential.
• Parkinson's disease: Contraindicated; haloperidol can severely worsen motor symptoms due to dopamine blockade.

Driving and alcohol

Haloperidol can cause marked sedation, dizziness, and blurred vision, significantly impairing the ability to drive or operate heavy machinery. Patients must avoid driving and hazardous activities until they know how the medication affects them. Alcohol must be strictly avoided because it can dangerously potentiate central nervous system depression, increase the risk of orthostatic hypotension, and exacerbate extrapyramidal side effects.

Dosage Instructions

• Schizophrenia and psychotic disorders: Initial dose is 0.5‑5 mg two to three times daily; the dose may be increased gradually by 0.5‑2 mg every 1‑3 days based on response. For severe or refractory cases, 5‑10 mg two or three times daily is common. The 10 mg tablet is used for patients who require higher doses. Maximum daily dose is 100 mg.
• Tourette syndrome: Start with 0.5 mg two to three times daily and increase by 0.5 mg increments until tics are controlled or side effects limit use. Doses above 10 mg/day are rarely needed.
• Acute agitation (oral): 5‑10 mg orally, repeated every 4‑8 hours as needed, with a maximum of 100 mg/day. Intramuscular injection is preferred for severe acute agitation.
• Administration: Take with a full glass of water; may be taken with food or milk to minimize stomach upset. Do not crush or chew tablets unless they are scored for splitting. Once‑daily dosing at bedtime can reduce daytime sedation once a stable dose is achieved.
• Missed dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not double the dose.
• Tapering: Abrupt discontinuation after prolonged therapy can cause withdrawal symptoms; gradual dose reduction is recommended.

Side Effects and Contraindications

Most common side effects (incidence >10%): Extrapyramidal symptoms including acute dystonia (spasms of the neck, jaw, back), akathisia (motor restlessness), and parkinsonism (tremor, rigidity, bradykinesia). Sedation, dry mouth, constipation, blurred vision, and orthostatic hypotension are also common.
Other adverse reactions: Weight gain, hyperprolactinemia (galactorrhea, gynecomastia, amenorrhea), photosensitivity, and urinary retention. Neuroleptic malignant syndrome (NMS) and tardive dyskinesia are serious complications of therapy.
Serious adverse reactions: QT prolongation leading to torsades de pointes and sudden cardiac death, especially with high doses or intravenous administration. Neuroleptic malignant syndrome (hyperthermia, muscle rigidity, autonomic instability, altered consciousness) is a medical emergency. Tardive dyskinesia may be irreversible. Agranulocytosis and cholestatic jaundice have been reported rarely.
Absolute contraindications: Severe toxic central nervous system depression or coma from any cause; Parkinson's disease; known hypersensitivity to haloperidol or any excipient; pre‑existing severe cardiovascular disease, particularly QT prolongation; severe hepatic impairment; and elderly patients with dementia‑related psychosis.

Drug Interactions

• QT‑prolonging agents (e.g., Class IA and III antiarrhythmics, macrolides, fluoroquinolones, methadone, certain antidepressants): Additive risk of life‑threatening ventricular arrhythmias; concomitant use is contraindicated or requires extreme caution with ECG monitoring.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): Increase haloperidol levels and risk of QT prolongation; dose reduction of haloperidol may be necessary.
• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): Decrease haloperidol levels, potentially reducing efficacy; increase haloperidol dose as needed.
• Lithium: May cause encephalopathic syndrome (confusion, disorientation, extrapyramidal symptoms) with concurrent use; monitor closely.
• Centrally acting depressants (alcohol, benzodiazepines, opioids): Profound sedation, respiratory depression, and hypotension; strict avoidance of alcohol is mandatory.
• Anticholinergic drugs: Additive anticholinergic effects (dry mouth, constipation, urinary retention) and increased risk of hyperthermia.
• Dopamine agonists (e.g., levodopa, bromocriptine): Mutual antagonism; haloperidol reduces the therapeutic effect of dopamine agonists.

Practical Advice

• Take Haldol exactly as prescribed. Do not stop abruptly, as withdrawal symptoms may occur.
• Avoid all alcoholic beverages during treatment.
• Be alert for signs of neuroleptic malignant syndrome (high fever, severe muscle stiffness, confusion, sweating, fast heart rate). Seek emergency help immediately if these develop.
• Report any involuntary movements of the tongue, face, mouth, or limbs, as these could be signs of tardive dyskinesia, which may become permanent.
• Use caution when driving or operating machinery, as haloperidol can cause significant drowsiness and slowed reaction time.
• Monitor for signs of orthostatic hypotension (dizziness when standing up), especially after the first dose; rise slowly from sitting or lying positions.
• Regular follow‑up including ECG, blood pressure, and assessment for movement disorders is essential.
• Store tablets at room temperature (15‑30°C / 59‑86°F) in a tightly closed container, away from light and moisture. Keep out of reach of children.
• Never share your medication with others, even if they have similar symptoms.

Alternative Medications

• Second‑generation antipsychotics: Aripiprazole (Abilify), risperidone (Risperdal), olanzapine (Zyprexa), quetiapine (Seroquel) have a lower risk of extrapyramidal symptoms but may cause metabolic side effects. Aripiprazole is also approved for Tourette syndrome.
• Other first‑generation antipsychotics: Chlorpromazine (Thorazine) is a low‑potency option with more sedation and anticholinergic effects; fluphenazine (Prolixin) is a high‑potency alternative similar to haloperidol.
• Clonidine and guanfacine: Alpha‑2 agonists used as first‑line agents for Tourette syndrome, especially in children.
• Benzodiazepines: Used acutely for agitation but not for long‑term management of psychosis due to dependence risk.
• Long‑acting injectable haloperidol decanoate: A depot formulation for maintenance therapy in schizophrenia to improve adherence.

Clinical Efficacy

Haloperidol is one of the most extensively studied first‑generation antipsychotics. In schizophrenia, it is highly effective for reducing positive symptoms (hallucinations, delusions) and preventing relapse; it remains a gold‑standard comparator in antipsychotic trials. Its high potency and low sedation make it suitable for treating acute agitation. For Tourette syndrome, haloperidol significantly reduces tic severity and frequency, though its use is often limited by extrapyramidal side effects. The risk of QT prolongation and extrapyramidal symptoms has led to the preference for second‑generation agents in many patients, but haloperidol remains a valuable option when cost, lack of metabolic side effects, or long‑term depot formulation is a consideration. Its efficacy is unequivocal when dosed appropriately with careful side‑effect monitoring.

Important:

Haldol (haloperidol) is a potent prescription antipsychotic that must be used under the supervision of a healthcare provider experienced in its use. It carries a boxed warning for increased mortality in elderly patients with dementia‑related psychosis and is not approved for this indication. Haloperidol can cause life‑threatening neuroleptic malignant syndrome, potentially irreversible tardive dyskinesia, and dangerous heart rhythm disturbances. An ECG must be checked before and during treatment to detect QT prolongation. Alcohol is strictly contraindicated. This drug may cause severe movement disorders, including acute dystonic reactions, which may require emergency treatment. Pregnant and breastfeeding women should use only if clearly needed, and the infant should be monitored. Do not stop the medication suddenly, as withdrawal can occur. Do not drive or operate machinery until you are certain you are not impaired. Keep out of reach of children; accidental ingestion can be fatal. In case of overdose, seek immediate emergency medical attention. This information is not a substitute for professional medical advice.

How to buy Generic Haldol no prescription U.S. Online Pharmacy